

REFERENCES

1. National Cancer Institute Thailand. No date. Statistic of cancer [online]. Available: <http://www.hci.go.th/statistic.htm> (2003, August15).
2. Souza B, How to study the pharmacology of medicinal plants in underdeveloped countries. *J.Ethnopharm.* 54: 131-138, 1996.
3. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu.Rev.Biochem.* 62: 385-429, 1993.
4. Krishna R and Mayer LD, Multidrug resistance (MDR) in cancer : mechanism, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drug. *Eur.J.Pharm.Sci.* 11: 265-283, 2000.
5. Ikegawa T, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Naito M, Tsuruo T, Ohtani H and Sawada Y, Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistance human myelogenous leukemia (K526/ADM) cells. *Cancer Lett* 160: 21-28, 2000.
6. Arona A and Shokla Y, Modulation of vinka-alkaloid induced P-glycoprotein expression by indole-3-carbinol. *Cancer Lett* 189: 167-173,2003.
7. Wang E, Casciano CN, Clement RP and Johnson WW, Inhibition of P-glycoprotein transport function by grapefruit juices psoralen. *Pharm Res.* 18: 432-438,2001.
8. Plouzek CA, Ciolino HP, Clarke R and Yeh GC, Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. *Eur.J.Cancer* 35: 1541-1545,1999.
9. Romiti N, Tongiani R, Cervelli F and Chieli E, Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. *Life Sci.* 62: 2349-2358, 1998.
10. Anuchapreeda S, Leechanachai P, Smith M, Ambudkar SV and Limtrakul P, Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB cells. *Biochem.Pharmacol.* 64: 573-582, 2002.

11. Lin HL, Liu TY, Wu CW and Chi CW, Berberine modulates expression of *mdr1* gene product and the responses of digestive track cancer cells to paclitaxel. *Br.J.Cancer* 81 416-422,1999.
12. Lin HL, Liu TY, Wu CW and Chi CW, Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. *Cancer* 85: 1939-1942, 1999.
13. Yang CS and Wang ZY, Tea and cancer. *J.Nat.Cancer.Inst.* 85: 1038-1049, 1993.
14. Sutherland RM, Cell and environment interactions in tumor microregions : the multicell spheroid model. *Science* 240: 177-184,1988.
15. Sutherland RM, Carlsson J, Durand R and Yuhas J, Spheroids in cancer research. *Cancer Res.* 41: 2980-2984,1981.
16. Schinkel AH and Jonker JW, Mammalian drug efflux transports of the ATP binding cassette (ABC) family : an overview. *Adv Drug Deliv Rev.* 55: 3-29, 2003.
17. O'Brien ML and Tew KD, Glutathione and related enzymes in multidrug resistance. *Eur.J.Cancer.* 32A: 967-978, 1996.
18. Kramer RA, Zakher J and Kim G, Role of the glutathione redox cycle in acquired and de Novo multidrug resistance. *Science* 241: 694-697, 1988.
19. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA and Weichselbaum RR, Increased glutathione peroxidase activity in human sarcoma cell line with inherent doxorubicin resistance. *Cancer Res.* 51: 521-527, 1991.
20. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosado JM, Stewart V, Krishna S and Hindenburg AA. *Cancer Res.* 49: 4120-4125, 1989.
21. Versantvoort C, Broxterman HJ, Bagrij T, Schepe RJ and Twentyman PR, Regulation by glutathione of drug transport in multidrug resistance human lung tumor cell line overexpressing multidrug resistance associated protein. *Br.J.Cancer.* 72: 82-89, 1995.
22. Lowe SW, Bodis S, MaClatchey A, Remington L, Ruley HL, Fisher DE, Housman DE and Jacks T, p53 Status and the efficacy of cancer therapy in vivo. *Science* 267: 1456-1462, 1995.

23. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild type p53 gene. *Cancer Res.* 54: 2287-2291, 1994.
24. Hickman JA, Apoptosis and chemotherapy resistance. *Eur.J.Cancer.* 32A: 921-926, 1996.
25. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N, Molecular targeting therapy of cancer : drug resistance, apoptosis and survival signal. *Cancer Sci.* 94: 15-21, 2003.
26. Broxterman HJ, Lankelma J and Hoekman K, Resistance to cytotoxic and anti-angiogenic anticancer agents : similarities and differences. *Drug Resist updat* 6: 111-127, 2003.
27. Aurelium BioPharma Inc. [No date]. "Why drug resistance". [Online]. Available: <http://www.aureliumbiopharma.com/images/Drug-resistance>. (2003, November29)
28. Lehnert M, Clinical multidrug resistance in cancer : a multifactorial problem. *Eur.J.Cancer.* 32A: 912-920, 1996.
29. Abolhoda A, Wilson AE, Rass H, Danenberg PV, Burt M and Scotto KW, Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. *Clin.Cancer.Res.* 5: 3352-3356, 1999.
30. Leith CP, Kopecky KJ, Chen IM, Eijdens L, Slovak ML, MaConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and Willman CL, Frequency and clinical significance of the expression of the multidrug resistance protein MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia : a southwest oncology group study. *Blood* 94: 1086-1099, 1999.
31. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukculis GK, Kuszak JR, Klusens TM, Saclaride TJ, Roninson JB and Coon JS, Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. *Cancer Res.* 51: 2720-2726, 1991.
32. Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick R, Skorecki KL and Warner E, Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade and stage. *Clin.Cancer.Res.* 1: 1611-1615, 1995.
33. Nature publishing group. 2002. "Gene therapy to protect haematopoietic cell from cytotoxic cancerdrug"[Online]. Available:<http://www.nature.com/nrc/journal/v2/n6/images/nrc823-f3.gif>. (2003, November29)

34. Dantzig AH, Alwis DP and Burgess M, Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. *Adv drug deliv rev.* 55: 133-150, 2003.
35. Chin JE, Soffir R, Noonan KE, Choi K and Roninson IB, Structure and expression of the human MDR (P-glycoprotein) gene family. *Mol.Cell.Biol.* 9: 3808-3820, 1989.
36. Ng WF, Sarangi F, Zastawny RL, Veinot DL and Ling V, Identification of members of the P-glycoprotein multigene family. *Mol.Cell.Biol.* 9: 1224-1232, 1989.
37. Smitt JJ, Schinkel AH, Oude ER, Groen AK and Wagenaar E, Homozygous disruption of the murine *mdr2* P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. *Cell* 75: 451-462, 1993.
38. Shen DW, Fojo AT, Chin JE, Roninson IB, Richert N, Pastan I and Gotterman MM. Human multidrug resistance cell line: increased MDR1 expression can precede gene amplification. *Science* 232: 643-645, 1986
39. Fojo AT, Whang-Peng J, Gottesman MM and Pastan I, Amplification of DNA sequences in human multidrug resistance KB carcinoma cells. *Proc.Natl.Acad.Sci.USA.* 82: 7661-7665, 1985.
40. Labialle S, Gayet L, Marthinet E, Rigal D and Baggetto LG, Transcriptional regulators of the human multidrug resistance 1 gene: recent views. *Biochem.Pharm.* 64: 943-948, 2002.
41. Bellamy WT, P-glycoprotein and multidrug resistance. *Annu.Rev.Pharmacol.Toxicol.* 36: 161-183, 1996.
42. Cordon CC, O'brien JP, Casel D, Rittman GL and Biedler JL, Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sites. *Proc.Natl.Acad.Sci.USA.* 86: 695-698, 1989.
43. Chaudhary PM and Roninson JB, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cell. *Cell* 66: 85-94, 1991.
44. Yang CP, Cohen D, Greenberger LM, Hsu SI, Horwitz SB, Differential transport properties of two *mdr* gene products are distinguished by progesterone. *J.Biol.Chem.* 265: 10282-10288, 1990.
45. Schinkel AH, Wagenaar E, Mol CA and Deemter CV, P-glycoprotein in the blood brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J.Clin.Invest.* 97: 2517-2524, 1996.

46. Grogan TM, Spier CH, Salmon SE, Matzner M and Rybski J, P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. *Blood* 81: 490-495, 1993.
47. Fromm MF, The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. *Adv Drug Deliv Rev.* 54: 129-1310, 2002.
48. Zhang JT and Ling V, Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. *J.Biol.Chem.* 266: 18224-18232, 1991.
49. Zhang JT, Duthie M and Ling V, Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. *J.Biol.Chem.* 268: 15101-15110, 1993.
50. Shach WR, Calayay MC and Lingappa VR, Evidence for an alternate model of human P-glycoprotein structure and biogenesis. *J.Biol.Chem.* 268: 6903-6908, 1993.
51. Schinkel AH, Kemp S, Dolle M, Rudenko G and Wagenaar E, N-glycosylation and deletion mutations of the human MDR1 P-glycoprotein. *J.Biol.Chem.* 263: 7474-7481, 1993.
52. Ambudkar SV, Key S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM, Biochemical, cellular and pharmacological aspects of the multidrug transporter. *Annu.Rev.Pharmacol.Toxicol.* 39: 361-398, 1999.
53. Zhang X, Collins KL and Greenberger LM, Functional evidence that transmembrane 11 and 12 form part of the drug binding domain in P-glycoprotein encoded by MDR1. *J.Biol.Chem.* 270: 5441-5448, 1995.
54. Loo TW and Claeke DM, Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide binding fold abolishes drug stimulated ATPase activity. *J.Biol.Chem.* 270: 22957-22961, 1995.
55. Muller M, bakos E, Welker E, Varadi A and germann UA, Altered drug stimulated ATPase activity in mutants of the human multidrug resistance protein. *J.Biol.Chem.* 271: 1877-1883, 1996.
56. Urbatsch IL, Sankaran B, Bhagat S and Senior AE, Both P-glycoprotein nucleotide binding sites are catalytically active. *J.Biol.Chem.* 270: 26956-26961, 1995.
57. Loo TW and Clarke DM, Membrane topology of a cysteine less mutant of human P-glycoprotein. *J.Biol.Chem.* 270: 843-848, 1995.

58. Juliano RL and Ling V, A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. *Biochem.Biophys.Acta.* 455: 1285-1288, 1976.
59. Roepe PD, Wei LY, Cruz J and Carlson D, Lower electrical membrane potential and altered pH(i) homeostasis in multidrug resistance (MDR) cell further characterization of a series of MDR cell line expressing different level of P-glycoprotein. *Biochemistry* 32: 11042-11056, 1993.
60. Hasmann M, Valet GK, Tapiero H, Trevorrow K and Lampidis T, Membrane potential differences between adriamycin sensitive and resistance cells as measured by flow cytometry. *Biochem Pharmacol* 38: 305-312,1989.
61. Roepe PD, Analysis of the steady state and initial rate of doxorubicin efflux from a series of multidrug resistant cells expressing different level of P-glycoprotein. *Biochemistry* 31: 12555-12564, 1992.
62. Germann UA, P-glycoprotein – a mediator of multidrug resistance in tumour cells. *Eur J Cancer* 32A: 927-944, 1996.
63. Boscobomik D, Gupta RS and Epanand RM, Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells. *Br.J.Cancer* 61: 568-572, 1990.
64. Ruetz S and Gros P, Functional expression of P-glycoproteins in secretory vesicles. *J.Biol.Chem.* 269: 12277-12284, 1994.
65. Sharom FJ, Yu X and Doige CA, Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. *J.Biol.Chem.* 268: 24197-24202, 1993.
66. Sauna ZE, Smith MM, Müller M, Kerr KM and Ambudkar SV, The mechanism of action of multidrug resistance linked P-glycoprotein. *J Bioenerg Biomembr.* 33: 481-491, 2001.
67. Higgins CF and Gottesman MM, Is the multidrug transporter a flippase?. *TIBS* 17: 18-21, 1992.
68. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res.* 41: 1967-1972, 1981.

69. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y, Increased accumulation of vincristine and adriamycin in drug resistant P388 tumors cell following incubation with calcium antagonists and calmodulin inhibitors. *Cancer Res.* 42: 4730-4733, 1982.
70. Ford JM, Experimental reversal of P-glycoprotein mediated multidrug resistance by pharmacological chemosensitizers. *Eur.J.Cancer.* 32A: 991-1001, 1996.
71. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR and Wood AJ, P-glycoprotein and cytochrom P450 3A inhibition : dissociation of inhibitory potencies. *Cancer Res.* 59: 3944-3948, 1999.
72. Lum BL and Gosland MP, MDR expression in normal tissues : pharmacologic implications for the clinical use of P-glycoprotein inhibitors. *Hematol.Oncol.Clin.North.Am.* 9: 319-336, 1995.
73. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank BS and Tewksbury DA, The effect of cyclosporin on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. *Cancer* 74: 834-841, 1994.
74. Thomas H and Coley HM, Overcoming multidrug resistance in cancer : an update on the clinical strategy of inhibiting P-glycoprotein. *Cancer Control* 10: 159-165, 2003.
75. Horie H and Kohata K, Analysis of tea components by high performance liquid chromatography and high performance capillary electrophoresis. *J.Chromatogr A.* 881: 425-438, 2000.
76. Yang CS, Maliakal P and Meng X, Inhibition of carcinogenesis by tea. *Annu.Rev.Pharmacol.* 42: 25-54, 2002.
77. Pietta PG, Flavonoids as antioxidants. *J.Nat.Prod.* 63: 1035-1042, 2000.
78. Aherne SA and O'Brien NM, Dietary flavonols : chemistry, food content and metabolism. *Nutrition* 18: 75-81, 2002.
79. Heim KE, Tagliaferro AR and Bobilya DJ, Flavonoid antioxidants : chemistry, metabolism and structure activity relationships. *J.Nutr.Biochem.* 13: 572-584, 2002.
80. Bravo L, Polyphenols : chemistry, dietary sources, metabolism and nutritional significance. *Nutr.Rev.* 56: 317-333, 1998.
81. Demeule M, Brossard M, Page' M, Gingras D and Béliveau R, Matrix metalloproteinase inhibition by green tea catechins. *Biochim.Biophys.Acta.* 1478: 51-60, 2000.

82. Wang ZY, Huang MT, Lou YR, Xie J, Reuhl KR, Newmark HL, Ho CT, Yang CS and conney AH, Inhibitory effects of black tea, green tea, decaffeinated black tea and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz(a)anthracene initiated SKH-1 mice. *Cancer Res.* 54: 3428-3435, 1994.
83. Yang CS and Wang ZY, Tea and cancer. *J.Nat.Cancer.Inst* 85: 1038-1048, 1993.
84. Ames BN, Shigenaga MK and Hagen TM, Oxidant, antioxidant and degenerative disease of aging. *Proc.Natl.Acad.Sci.USA.* 90: 7915-7922, 1993.
85. Xu Y, Ho CT and Amin SG, Inhibition of tobacco-specific nitrosamine induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. *Cancer Res.* 52: 3875-3879, 1992.
86. Bhimami R and Frenkel K, Supression of H₂O₂ production on oxidative DNA damage in HeLa cells by (-)- epigallocatechin gallate (EGCG). *Proc.Am.Assoc.Cancer.Res.* 32: 126,1991
87. Khan WA, Wang ZY, Alhar M, Bickers DR and Mukhtar H, Inhibition of the skin tumorigenicity of (+)-7, $\beta\gamma\alpha$ -dihydroxy-9 α ,10 α -epoxide-7,8,9,10-tetrahydrobenzene(a) pyrene by tannic acid, green tea polyphenol and quercetin in SENCAR mice. *Cancer Lett* 42: 7-12, 1988.
88. Khan SG, Katiyar SK and Agarwal R, Enhancement of antioxidant and phaseII enzymes by oral feeding of green tea polyphenol in drinking water to SKH-1 hairless mice : possible role in cancer chemoprevention. *Cancer Res.* 52: 4050-4052, 1992.
89. Kong AT, Yu R, Hebbar V, Chen C, Owuor E, Hu R, Ec R and Mandlekar S, Signal transduction events elicited by cancer prevention compounds. *Mutat.Res.* 480-481: 231-241, 2001.
90. Lin J, Liang Y and Lin-Shia S, Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockades. *Biochem.Pharmacol.* 58: 911-915, 1999.
91. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Tshii S, Pastan I and Gottesman MM, Multiple drug resistant human KB carcinoma cells independently selected for high level resitance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins. *J.Biol.Chem.* 261: 7762-7770, 1986.

92. Mosmann T, Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assay. *J.Immunol.Methods* 65: 55-63, 1983.
93. Bates SE, LeeJS, Dickstein B, Spolyar M and FOLO AT, Differential modulation of P-glycoprotein transport by protein kinase inhibition. *Biochemistry* 32: 9156-9164, 1993.
94. Plouzek CA, Ciolino HP, Clarke R and Yeh GC, Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. *Eur.J.Cancer.* 35: 1541-1545, 1999.
95. Jodoin J, Demeule M and Béliveau R, Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. *Biochim.Biophys.Acta* 1542: 149-159, 2002.
96. Kawai K, Kamatani N, georges E and Ling V, Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum (II). *J.Biol.Chem.* 265: 13137-13142, 1990.
97. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685, 1970.
98. Lowry OH, Rosebrough NJ, Lowis FA and Randall RJ, Protein measurement with the Folin phenol reagent. *J.Biol.Chem.* 193: 265-275, 1951.
99. Dunn MJ, Electrophoresis analysis methods. In protein purification methods: a practical approach. Oxford university press, New York, 18-19, 1989.
100. Chu TM, Lin TH and Kawinski E, Detection of soluble P-glycoprotein in culture media and extracellular fluids. *Biochem.Biophys.Res.Commun.* 203: 506-512, 1994.
101. Phang JM, Poore CM, Lopaczynska J and Yeh GC, Flavonol stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug resistance breast cancer cells. *Cancer Res.* 53: 5977-5981, 1993.
102. Castro AF, Horton JK, Vanoye CG and Altenberg GA, Inhibition of drug transport by genistein in multidrug resistance cells expressing P-glycoprotein. *Biochem.Pharmacol.* 58: 1723-1733, 1999.
103. Uesato S, Kitagawa Y, Kamishimoto M, Kumagai A, Hori H and Nagasawa H, Inhibition of green tea catechin against the growth of cancerous human colon and hepatic epithelial cells. *Cancer Lett.* 170: 41-44, 2001.

104. Wang E, Barecki-Roach M and John W, Elevation of P-glycoprotein function by a catechin in green tea. *Biochem.Biophys.Res.Commun.* 297: 412-418, 2002.
105. Sadzuka Y, Sugiyama T and Sonobe T, Efficacies of tea components on doxorubicin induced antitumor activity and reversal of resistance. *Toxicol.Lett.* 114: 155-162, 2000.
106. Boufford DY, Ohkawa T, Kijima H, Iric A, Suzuki T, Curcino LD, Holm PS, Sassami A and Scanlon KJ, Oligonucleotide modulation of multidrug resistance. *Eur.J.Cancer.* 32A: 1010-1018, 1996.
107. Mei Y, Wei X and Liu J, Reversal of cancer multidrug resistance by tea polyphenol in KB cells. *J chromatography* 15: 260-265, 2003.
108. Zhu A, Wang X and Guo Z, Study of the tea polyphenol as a reversal agent for carcinoma cell lines multidrug resistance (study of TP as a MDR reversal agent). *Nucl.Med.Biol.* 28: 735-740, 2001.
109. Jordan MA, Thrower D and Wilsor L, Mechanism of inhibition of cell proliferation by vinca alkaloids. *Cancer Res.* 51: 2212-2222, 1991.
110. Hande KR, Etoposide: four decades of development of a topoisomerase II inhibitors. *Eur.J.Cancer.* 34: 1514-1521, 1998.
111. Chuang TC, Lee YJ, Liu JY, Lin YS, Li JW, Wang V, Law SL and Kao MC, EBNA1 may prolong G(2)/M phase and sensitize HER1/neu-overexpressing ovarian cancer cells to both topoisomerase II-targetting and paclitaxel drugs. *Biochem.Biophys.Res.Commun.* 307: 653-659, 2003.
112. Boldt S, Weidle UH and Kolch W, The role of MAPK pathways in the action of chemotherapeutic drugs. *Carcinogenesis* 23: 1831-1838, 2002.
113. Persons DL, Yazlovitskaya EM, Cui W and Pelling JC, Cisplatin-induced activation of mitogen-induced protein kinases in ovarian carcinoma cells : inhibition of extracellular signal regulated kinase activity increase sensitivity of cisplatin. *Clin.Cancer.Res.* 5: 1007-1014, 1999.
114. Wang X, martindale JL and Holbrook NJ, Requirement for ERK activation in cisplatin induced apoptosis. *J.Biol.Chem.* 275: 39435-39443, 2000.
115. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP and Chambers TC, The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated

- by the antitumor agents vinblastine, doxorubicin and etoposide. *Biochem.Pharmacol.* 66:459-469, 2003.
116. Pan Z, Bruening W, Giasson BI, Lee YH and Godwin AK, γ -synuclein promotes cancer cell survival and inhibits stress and chemotherapy drug induced apoptosis by modulating MAPK pathway. *J.Biol.Chem.* 277: 35050-35060, 2002.
117. Barančík M, Boháčová V, Kvačkajová J, Hudecová S, Krizanová O and Breier A, SB203580, a specific inhibitor of p38 MAPK pathway, is a new reversal agent of P-glycoprotein mediated multidrug resistance. *Eur.J.Pharm.Sci.* 14: 29-36, 2001.
118. Levites Y, Amit T, Youdim M and Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle gene in green tea polyphenol (-)- epigallocatechin-3-gallate neuroprotective action. *J.Biol.Chem.* 277; 30574-30580, 2002.
119. Chen C, Yu R, Owuor ED and Kong NT, Activation of antioxidant response element (ARE), mitogen activated protein kinase (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. *Arch.Pharm.Res.* 23: 605-612, 2000.